<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460329</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1163</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101163</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Vaccination is the best preventive measure for SARS-CoV-2 infection; however, efficacy is lower in cancer patients. During the pandemic period, Mexico was characterized by the use of seven different COVID-19 vaccine platforms, and oncologic patients were not prioritized for vaccination. We report the outcomes of COVID-19 in cancer patients after the beginning of the national vaccine campaign in Mexico.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All patients with cancer and COVID-19 diagnosed at Instituto Nacional de Cancerología from 14 February 2021 to 28 February 2022 were included. Primary outcomes were the proportion of individuals who required hospital admission and/or invasive mechanical ventilation, according to the vaccination status; 30-day mortality; the period of infection; and other cancer-related variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 691 patients were included; 524 (76%) had solid tumors (STs), and 167 (24%) had hematologic malignancies (HMs). Patients infected in the first two periods, had lower rates of vaccination and higher rates of mortality and hospitalization compared to those infected in the Omicron period. In the multivariate analysis, vaccination status was independently associated with hospitalization in patients with STs (aOR 0.38, 95%CI 0.19-0.75, <i>p</i> = 0.005), but it was not associated with invasive mechanical ventilation and 30-day mortality. In those with HMs, vaccination status was not associated with any outcome; in this group, only recent chemotherapy and time of infection were associated with invasive ventilation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vaccination significantly reduced hospital admissions in patients with STs. Infections occurring during the Omicron period were associated with improved outcomes in both ST and HM patients. Despite having a lesser impact in immunosuppressed patients, vaccination is an essential strategy, and access to vaccination campaigns in patients with cancer needs to be prioritized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrientos-Flores</LastName><ForeName>Corazón</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7449-5961</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col. Sección 16 Belisario Domínguez, Tlalpan, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilar-Compte</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col. Sección 16 Belisario Domínguez, Tlalpan, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Rivera</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col. Sección 16 Belisario Domínguez, Tlalpan, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villaseñor-Echavarri</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5750-884X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col. Sección 16 Belisario Domínguez, Tlalpan, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Onraet</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8627-404X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col. Sección 16 Belisario Domínguez, Tlalpan, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">hematologic malignancies</Keyword><Keyword MajorTopicYN="N">solid tumors</Keyword></KeywordList><CoiStatement>DVC reports a relationship with Janssen Pharmaceuticals Inc and Pfizer Inc, including consulting or advisory work, as well as speaking and lecture fees. AMO reports a relationship with Pfizer Inc, including lecture fees.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460329</ArticleId><ArticleId IdType="pmc">PMC11512203</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101163</ArticleId><ArticleId IdType="pii">vaccines12101163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giannakoulis V.G., Papoutsi E., Siempos I.I. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob. Oncol. 2020;6:799–808. doi: 10.1200/GO.20.00225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO.20.00225</ArticleId><ArticleId IdType="pmc">PMC7328119</ArticleId><ArticleId IdType="pubmed">32511066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M., Lei X., Zhao H., Scheet P., Giordano S.H. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients with or without Cancer. JAMA Oncol. 2022;8:69–78. doi: 10.1001/jamaoncol.2021.5148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761–1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti C., Curigliano G. Commentary: SARS-CoV-2 vaccines and cancer patients. Ann. Oncol. 2021;32:569–571. doi: 10.1016/j.annonc.2020.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.12.019</ArticleId><ArticleId IdType="pmc">PMC7831848</ArticleId><ArticleId IdType="pubmed">33450404</ArticleId></ArticleIdList></Reference><Reference><Citation>Linardou H., Spanakis N., Koliou G.-A., Christopoulou A., Karageorgopoulou S., Alevra N., Vagionas A., Tsoukalas N., Sgourou S., Fountzilas E., et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers. 2021;13:4621. doi: 10.3390/cancers13184621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13184621</ArticleId><ArticleId IdType="pmc">PMC8466969</ArticleId><ArticleId IdType="pubmed">34572848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A., Morgan R.L., Shumaker A.H., Baden L.R., Cheng V.C.-C., Edwards K.M., Gallagher J.C., Gandhi R.T., Muller W.J., Nakamura M.M., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2024;78:e250–e349. doi: 10.1093/cid/ciac724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac724</ArticleId><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cancer Letter [Internet]  Cancer Groups Urge CDC to Prioritize Cancer Patients for COVID-19 Vaccination. 2021.  [(accessed on 4 January 2024)].  Available online:  https://cancerletter.com/covid-19-cancer/20210108_2/</Citation></Reference><Reference><Citation>Lawrence L. Cancer Therapy Advisor. 2022. NCCN Updates Recommendations for COVID-19 Vaccination.  [(accessed on 4 January 2024)].  Available online:  https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/nccn-updates-recommendations-for-covid-19-vaccination/</Citation></Reference><Reference><Citation>Song Q., Bates B., Shao Y.R., Hsu F.-C., Liu F., Madhira V., Mitra A.K., Bergquist T., Kavuluru R., Li X., et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients with Cancer: Real-World Evidence from the National COVID Cohort Collaborative. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2022;40:1414–1427. doi: 10.1200/JCO.21.02419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02419</ArticleId><ArticleId IdType="pmc">PMC9061155</ArticleId><ArticleId IdType="pubmed">35286152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Kaelber D.C., Xu R., Berger N.A. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients with Cancer in the US Between December 2020 and November 2021. JAMA Oncol. 2022;8:1027–1034. doi: 10.1001/jamaoncol.2022.1096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2022.1096</ArticleId><ArticleId IdType="pmc">PMC9305383</ArticleId><ArticleId IdType="pubmed">35394485</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerril-Gaitan A., Vaca-Cartagena B.F., Ferrigno A.S., Mesa-Chavez F., Barrientos-Gutiérrez T., Tagliamento M., Lambertini M., Villarreal-Garza C. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: A systematic review and meta-analysis. Eur. J. Cancer. 2022;160:243–260. doi: 10.1016/j.ejca.2021.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.10.014</ArticleId><ArticleId IdType="pmc">PMC8548030</ArticleId><ArticleId IdType="pubmed">34794855</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V., Pernat C.A., Gavralidis A., St Denis K.J., Lam E.C., Spring L.M., Isakoff S.J., Farmer J.R., Zubiri L., Hobbs G.S., et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients with Cancer: The CANVAX Cohort Study. J. Clin. Oncol. 2022;40:12–23. doi: 10.1200/JCO.21.01891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.01891</ArticleId><ArticleId IdType="pmc">PMC8683230</ArticleId><ArticleId IdType="pubmed">34752147</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupo Técnico Asesor de Vacunación COVID-19 Priorización inicial y consecutiva para la vacunación contra SARS-CoV-2 en la población mexicana. Recomendaciones preliminares. Salud Pública México. 2021;63:288–309. doi: 10.21149/12399.</Citation><ArticleIdList><ArticleId IdType="doi">10.21149/12399</ArticleId><ArticleId IdType="pubmed">33989472</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO-2019-nCoV-Vaccines-SAGE_Recommendation-Ad5-nCoV-S-2022.1-eng.pdf [Internet]  [(accessed on 4 January 2024)].  Available online:  https://iris.who.int/bitstream/handle/10665/354409/WHO-2019-nCoV-vaccines-SAGE_recommendation-Ad5-nCoV-S-2022.1-eng.pdf?sequence=1.</Citation></Reference><Reference><Citation>Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Lister T.A. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J. Clin. Oncol. 2014;32:3059–3067. doi: 10.1200/JCO.2013.54.8800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.54.8800</ArticleId><ArticleId IdType="pmc">PMC4979083</ArticleId><ArticleId IdType="pubmed">25113753</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowchart-Moderate-Severe.pdf [Internet]  [(accessed on 4 January 2024)].  Available online:  https://covid19evidence.net.au/wp-content/uploads/FLOWCHART-MODERATE-SEVERE.pdf?=220615-00907.</Citation></Reference><Reference><Citation>Consejo Nacional de Humanidades Ciencias y Tecnologia, Vigilancia de variantes del virus SARS-COV-2.  [(accessed on 2 October 2024)].  Available online:  https://salud.conahcyt.mx/coronavirus/variantes/</Citation></Reference><Reference><Citation>Fendler A., de Vries E.G.E., GeurtsvanKessel C.H., Haanen J.B., Wörmann B., Turajlic S., von Lilienfeld-Toal M. COVID-19 vaccines in patients with cancer: Immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 2022;19:385–401. doi: 10.1038/s41571-022-00610-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00610-8</ArticleId><ArticleId IdType="pmc">PMC8916486</ArticleId><ArticleId IdType="pubmed">35277694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato D.J., Ferrante D., Aguilar-Company J., Bower M., Salazar R., Mirallas O., Sureda A., Bertuzzi A., Brunet J., Lambertini M., et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. Eur. J. Cancer. 2022;171:64–74. doi: 10.1016/j.ejca.2022.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2022.04.036</ArticleId><ArticleId IdType="pmc">PMC9124924</ArticleId><ArticleId IdType="pubmed">35704976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A.L., Labaki C., Hsu C.-Y., Bakouny Z., Balanchivadze N., Berg S.A., Blau S., Daher A., El Zarif T., Friese C.R., et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann. Oncol. 2022;33:340–346. doi: 10.1016/j.annonc.2021.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.12.006</ArticleId><ArticleId IdType="pmc">PMC8704021</ArticleId><ArticleId IdType="pubmed">34958894</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog Tzarfati K., Gutwein O., Apel A., Rahimi-Levene N., Sadovnik M., Harel L., Benveniste-Levkovitz P., Bar Chaim A., Koren-Michowitz M. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am. J. Hematol. 2021;96:1195–1203. doi: 10.1002/ajh.26284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26284</ArticleId><ArticleId IdType="pmc">PMC8420332</ArticleId><ArticleId IdType="pubmed">34185336</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez M., Roldán E., Fernández-Naval C., Villacampa G., Martinez-Gallo M., Medina-Gil D., Peralta-Garzón S., Pujadas G., Hernández C., Pagès C., et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022;6:774–784. doi: 10.1182/bloodadvances.2021006101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006101</ArticleId><ArticleId IdType="pmc">PMC8632354</ArticleId><ArticleId IdType="pubmed">34844263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahremand T., Yao J.A., Mill C., Piszczek J., Grant J.M., Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: A population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg. Health Am. 2023;20:100461. doi: 10.1016/j.lana.2023.100461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100461</ArticleId><ArticleId IdType="pmc">PMC9987330</ArticleId><ArticleId IdType="pubmed">36890850</ArticleId></ArticleIdList></Reference><Reference><Citation>De-la-Rosa-Martinez D., Aranda-Audelo M., Martin-Onraet A., Islas-Muñoz B., Perez-Jimenez C., Alatorre-Fernandez P., Cornejo-Juarez P., Ruiz-Garcia E., Zinser-Peniche P., Nuñez-Luna L., et al. Clinical characteristics and outcomes in a cohort of oncologic patients with COVID-19 during the first year of the pandemic in Mexico. Cancer Med. 2022;11:1827–1836. doi: 10.1002/cam4.4582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4582</ArticleId><ArticleId IdType="pmc">PMC9041085</ArticleId><ArticleId IdType="pubmed">35166033</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaroszewicz J., Kowalska J., Pawłowska M., Rogalska M., Zarębska-Michaluk D., Rorat M., Lorenc B., Czupryna P., Sikorska K., Piekarska A., et al. Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. Cancers. 2022;14:4720. doi: 10.3390/cancers14194720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14194720</ArticleId><ArticleId IdType="pmc">PMC9563758</ArticleId><ArticleId IdType="pubmed">36230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar A., Gonzalez-Lugo J.D., Goradia N., Gali R., Shapiro L.C., Pradhan K., Rahman S., Kim S.Y., Ko B., Sica R.A., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081–1090.e2. doi: 10.1016/j.ccell.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8179248</ArticleId><ArticleId IdType="pubmed">34133951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato D.J., Aguilar-Company J., Ferrante D., Hanbury G., Bower M., Salazar R., Mirallas O., Sureda A., Plaja A., Cucurull M., et al. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: Results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol. 2022;23:865–875. doi: 10.1016/S1470-2045(22)00273-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00273-X</ArticleId><ArticleId IdType="pmc">PMC9162476</ArticleId><ArticleId IdType="pubmed">35660139</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., de Silva T.I., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ángeles-Sistac D., Martin-Onraet A., Cornejo-Juárez P., Volkow P., Pérez-Jimenez C., Vilar-Compte D. Influenza in patients with cancer after 2009 pandemic AH1N1: An 8-year follow-up study in Mexico. Influenza Other Respir. Viruses. 2020;14:196–203. doi: 10.1111/irv.12704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12704</ArticleId><ArticleId IdType="pmc">PMC7040981</ArticleId><ArticleId IdType="pubmed">31747133</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Vaccine Tracker and Landscape [Internet]  [(accessed on 4 January 2024)].  Available online:  https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Kakkassery H., Carpenter E., Patten P.E.M., Irshad S. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends Mol. Med. 2022;28:1082–1099. doi: 10.1016/j.molmed.2022.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.07.006</ArticleId><ArticleId IdType="pmc">PMC9345889</ArticleId><ArticleId IdType="pubmed">35999131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.R.Y.B., Wong S.Y., Chai L.Y.A., Lee S.C., Lee M.X., Muthiah M.D., Tay S.H., Teo C.B., Tan B.K.J., Chan Y.H., et al. Efficacy of COVID-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ. 2022;376:e068632. doi: 10.1136/bmj-2021-068632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarnezhad Tameshkel F., Abedin Dargoush S., Amirkalali B., Javadi S., Ghiaseddin A., Alimohamadi Y., Basi A., Jamshidi Makiani M., Zamani F., Karbalaie Niya M.H. SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study. Front. Med. 2023;9:1095194. doi: 10.3389/fmed.2022.1095194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1095194</ArticleId><ArticleId IdType="pmc">PMC9893850</ArticleId><ArticleId IdType="pubmed">36743671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachman A., Iriani A., Sukrisman L., Rajabto W., Mulansari N.A., Lubis A.M., Cahyanur R., Prasetyawati F., Priantono D., Rumondor B.B., et al. A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA. PLoS ONE. 2023;18:e0281907. doi: 10.1371/journal.pone.0281907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281907</ArticleId><ArticleId IdType="pmc">PMC9977046</ArticleId><ArticleId IdType="pubmed">36857323</ArticleId></ArticleIdList></Reference><Reference><Citation>Simsek M., Yasin A.I., Besiroglu M., Topcu A., Sucuoglu Isleyen Z., Seker M., Turk H.M. The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer. J. Med. Virol. 2022;94:4138–4143. doi: 10.1002/jmv.27835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27835</ArticleId><ArticleId IdType="pmc">PMC9348062</ArticleId><ArticleId IdType="pubmed">35513241</ArticleId></ArticleIdList></Reference><Reference><Citation>Luangdilok S., Wanchaijiraboon P., Pakvisal N., Susiriwatananont T., Zungsontiporn N., Sriuranpong V., Sainamthip P., Suntronwong N., Vichaiwattana P., Wanlapakorn N., et al. Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine. Vaccines. 2022;10:1613. doi: 10.3390/vaccines10101613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101613</ArticleId><ArticleId IdType="pmc">PMC9608216</ArticleId><ArticleId IdType="pubmed">36298478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guven D.C., Incesu F.G.G., Yildirim H.C., Erul E., Chalabiyev E., Aktas B.Y., Yuce D., Arik Z., Kilickap S., Aksoy S., et al. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. Int. J. Cancer. 2023;152:679–685. doi: 10.1002/ijc.34280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.34280</ArticleId><ArticleId IdType="pmc">PMC9538436</ArticleId><ArticleId IdType="pubmed">36082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejri N., Berrazega Y., Ouertani E., Rachdi H., Bohli M., Kochbati L., Boussen H. Understanding COVID-19 vaccine hesitancy and resistance: Another challenge in cancer patients. Support. Care Cancer. 2022;30:289–293. doi: 10.1007/s00520-021-06419-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-021-06419-y</ArticleId><ArticleId IdType="pmc">PMC8286987</ArticleId><ArticleId IdType="pubmed">34279721</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnalla M., Basto-Abreu A., Stern D., Bautista-Arredondo S., Shamah-Levy T., Alpuche-Aranda C.M., Rivera-Dommarco J., Barrientos-Gutiérrez T. Acceptance, refusal and hesitancy of COVID-19 vaccination in Mexico: Ensanut 2020 COVID-19. Salud Pública México. 2021;63:598–606. doi: 10.21149/12696.</Citation><ArticleIdList><ArticleId IdType="doi">10.21149/12696</ArticleId><ArticleId IdType="pubmed">35099875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>